Norwood Immunology: Extraordinary General Meeting | Company Announcements

Monday 27 November, 2006

Norwood Immunology

Extraordinary General Meeting

Norwood Immunology Ld
27 November 2006


FOR IMMEDIATE RELEASE                                         27 November 2006
                                                                           



                           NORWOOD IMMUNOLOGY LIMITED


          EGM APPROVES ISSUE OF SHARES FOR FUNDRAISING AND ACQUISITION



Norwood Immunology Limited ('Norwood Immunology' or 'the Company') (AIM:NIM),
the company focused on the rejuvenation of the immune system, today announces
that further to its announcement on 31 October 2006, it has completed it's
Extraordinary General Meeting earlier today and all resolutions in order to
complete the £6.6m (approximately £6.2m net of expenses) fundraising with the
issue of the placement of 55,000,000 ordinary shares in the Company ('Placement
Shares') together with 48,014,489 ordinary shares in the Company ('Acquisition
Shares') as part consideration for a proposed acquisition ('Acquisition') of all
of the issued shares of Bestewil Holding B.V. ('Bestewil') and its 100%
subsidiary Virosome Biologicals B.V. were successfully passed and approved.


Application has been made for admission of new ordinary shares (comprising
55,000,000 Placement Shares, 48,014,489 Acquisition Shares and 1,315,435 Third
Party Shares as part payment for services provided by third parties in relation
to the Acquisition) (together the 'New Ordinary Shares') to the AIM market of
London Stock Exchange plc and dealings are expected to commence on 28 November
2006 in relation to the Acquisition Shares and Placing Shares and on 29 November
in relation to the Third Party Shares issued as part payment for services
provided by third parties in relation to the Acquisition.


The New Ordinary Shares will rank pari passu in all respects with the existing
ordinary shares of the Company.


For further information contact:


Richard Williams, Chief Executive Officer, Norwood Immunology Limited
www.norwoodimmunology.com
+44 (0)7860 295153


Buchanan Communications - Lisa Baderoon, Mark Court, Mary-Jane Johnson,
+44 (0)207 466 5000


KBC Peel Hunt Ltd - Capel Irwin, Megan MacIntyre
+44 (0) 20 7418 8900



                      This information is provided by RNS
            The company news service from the London Stock Exchange

Investegate takes no responsibility for the accuracy of the information within the site.

The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.